Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [11C]Flumazenil PET

详细信息    查看全文

• 作者：Peter J. H. Scott ; Xia Shao ; Timothy J. Desmond ; Brian G. Hockley ; Phillip Sherman ; Carole A. Quesada ; Kirk A. Frey ; Robert A. Koeppe ; Michael R. Kilbourn ; Nicolaas I. Bohnen
• 刊名：ACS Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：August 11, 2016
• 年：2016
• 卷：7
• 期：8
• 页码：746-750
• 全文大小：286K
• 年卷期：0
• ISSN：1948-5875

文摘

Clarithromycin is a potential treatment for hypersomnia acting through proposed negative allosteric modulation of GABA_A receptors. We were interested whether this therapeutic benefit might extend to Parkinson’s disease (PD) patients because GABAergic neurotransmission is implicated in postural control. Prior to initiating clinical studies in PD patients, we wished to better understand clarithromycin’s mechanism of action. In this work we investigated whether the proposed activity of clarithromycin at the GABA_A receptor is associated with the benzodiazepine binding site using in vivo [¹¹C]flumazenil positron emission tomography (PET) in primates and ex vivo [³H]flumazenil autoradiography in rat brain. While the studies demonstrate that clarithromycin does not change the K_d of FMZ, nor does it competitively displace FMZ, there is preliminary evidence from the primate PET imaging studies that clarithromycin delays dissociation and washout of flumazenil from the primate brain in a dose-dependent fashion. These findings would be consistent with the proposed GABA_A allosteric modulator function of clarithromycin. While the results are only preliminary, further investigation of the interaction of clarithromycin with GABA receptors and/or GABAergic medications is warranted, and therapeutic applications of clarithromycin alone or in combination with flumazenil, to treat hyper-GABAergic status in PD at minimally effective doses, should also be pursued.